分化抗原簇63在非小细胞肺癌中的表达及临床意义

目的 检测分化抗原簇63(cluster of differentiation 63,CD63)在非小细胞肺癌(non-small-cell lung cancer,NSCLC)组织中的表达水平与临床特征和生存的相关性.方法 收集2013年6月至2015年1月在安阳市第二人民医院接受手术治疗的NSCLC患者126例,收...

Expression of differentiation antigen cluster 63 in non-small cell lung cancer and its clinical significance

Objective To detect the correlation between the expression level of cluster 63 of CD63 in non-small-cell lung cancer(NSCLC)tissue and clinical features and survival.Methods A total of 126 NSCLC patients who underwent surgical treatment in our hospital from June 2013 to January 2015 were collected,and the general clinical data and tumor tissue samples of the patients were collected.CD63 expression level in NSCLC tissue was detected by immunohistochemical experiment,and it was divided into the high expression group and the low expression group.Chi-square test was used to analyze the correlation between the expression of CD63 and clinical characteristics of patients.Kaplan-Meier analysis method was used to draw the survival curve.Log-rank test was used to compare the survival rate of CD63 high and low expression groups.The cox regression model performed univariate and multivariate analysis of independent risk factors affecting patient prognosis.Results The high expression rate of CD63 in NSCLC tissues was 55.6%(70/126),and the low expression rate was 44.4%(56/126).The proportion of patients with T 3-T 4 stage,positive lymphatic metastasis,andⅢstage of TNM stage in the CD63 low expression group was higher than that in the CD63 high expression group.The 5-year median survival time and PFS of the CD63 low expression group were lower than that of the CD63 high expression group(log-rank=5.272,P=0.022;log-rank=6.813,P=0.009).Tumor stage,lymph node metastasis,TNM stageⅢ-Ⅳ,and low expression of CD63 were all independent risk factors for the prognosis of patients with NSCLC.Conclusion Low CD63 expression is associated with tumor stage,lymph node metastasis,TNM stage and prognosis in NSCLC patients.